Marina Biotech, Inc. is a fully integrated, commercial stage biopharmaceutical company delivering proprietary drug therapeutics for significant unmet medical needs in the U.S., Europe and additional markets. Our portfolio of products focuses on fixed dose combinations FDC in hypertension, arthritis, pain and oncology allowing for innovative solutions to such unmet medical needs. Our approach is meant to reduce clinical risk and accelerate time to market by shortening the clinical development program through leveraging what is already known or can be learned in our proprietary Patient Level Database. We currently have one commercial and three clinical development programs underway: i Prestalia , a single pill FDC of perindopril and amlodipine, which has been approved by the FDA and is actively marketed in the U.S. ii our next generation celecoxib program drug candidates for the treatment of acute and chronic pain, IT and IT , each of which is an FDC of celecoxib and either lisinopril IT or olmesartan IT iii CEQ , an oral delivery of small interfering RNA against beta catenin, combined with IT to suppress polyps in the precancerous syndrome and orphan indication Familial Adenomatous Polyposis and iv CEQ combined with IT to treat Colorectal Cancer.
Quote | Moderna Inc. (NASDAQ:MRNA)
Last: | $106.56 |
---|---|
Change Percent: | -0.46% |
Open: | $111.1 |
Close: | $106.56 |
High: | $112 |
Low: | $105.95 |
Volume: | 3,930,201 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
News | Moderna Inc. (NASDAQ:MRNA)
2024-03-28 09:06:17 ET “Biotech industry has found its footing again”, says Karen Andersen – a Morningstar strategist. Here are the top U.S. based stocks within this space that are particularly worth owning for 2024. Vertex Pharmaceuticals Inc (NASDAQ: VRTX) ...
2024-03-28 09:00:06 ET Michael Yee from Jefferies issued a price target of $125.00 for MRNA on 2024-03-28 07:49:00. The adjusted price target was set to $125.00. At the time of the announcement, MRNA was trading at $110.59. The overall price target consensus is at $173.6...
Message Board Posts | Moderna Inc. (NASDAQ:MRNA)
Subject | By | Source | When |
---|---|---|---|
Cathie Wood's ARK Innovation ETF buys shares of | axelvento | investorshub | 05/01/2023 4:39:04 AM |
Believe in what | Vexari | investorshub | 05/01/2023 4:25:38 AM |
the important thing is to believe not to hope! | axelvento | investorshub | 05/01/2023 4:14:06 AM |
The thought of overthinking without explanation | Vexari | investorshub | 04/30/2023 8:03:20 PM |
Without understanding | Vexari | investorshub | 04/29/2023 9:23:49 PM |
News, Short Squeeze, Breakout and More Instantly...
2024-03-28 09:06:17 ET “Biotech industry has found its footing again”, says Karen Andersen – a Morningstar strategist. Here are the top U.S. based stocks within this space that are particularly worth owning for 2024. Vertex Pharmaceuticals Inc (NASDAQ: VRTX) ...
2024-03-28 09:00:06 ET Michael Yee from Jefferies issued a price target of $125.00 for MRNA on 2024-03-28 07:49:00. The adjusted price target was set to $125.00. At the time of the announcement, MRNA was trading at $110.59. The overall price target consensus is at $173.6...
2024-03-28 07:15:01 ET Goldman Sachs analyst issues BUY recommendation for MRNA on March 28, 2024 05:33AM ET. The previous analyst recommendation was Buy. MRNA was trading at $110.59 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...